Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | SELE | P16581 | 2/20 | 0.43 |
| ▸ | IGF2R | P11717 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | FGF1 | P05230 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | SELL | P14151 | 1/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587627 | 0.96 | AMY1A (0.47) | AMY1ASELEIGF2RSTAT3ALDH1A1 | |
| SCHEMBL16869952 | 0.96 | AMY1A (0.47) | AMY1ASELEIGF2RSTAT3ALDH1A1 | |
| SCHEMBL19480243 | 0.93 | IGF2R (0.42) | AMY1ASELEIGF2RSTAT3ALDH1A1 | |
| SCHEMBL16866291 | 0.89 | AMY1A (0.41) | AMY1ASELEIGF2RSTAT3ALDH1A1 | |
| SCHEMBL19480247 | 0.89 | IGF2R (0.46) | AMY1ASELEIGF2RSTAT3ALDH1A1 | |
| SCHEMBL19480148 | 0.89 | IGF2R (0.46) | AMY1ASELEIGF2RSTAT3ALDH1A1 | |
| SCHEMBL26032277 | 0.86 | AMY1A (0.54) | AMY1ASELEIGF2RSTAT3ALDH1A1 | |
| SCHEMBL27279098 | 0.85 | AMY1A (0.51) | AMY1ASELEIGF2RSTAT3FGF1 | |
| SCHEMBL22026382 | 0.84 | IGF2R (0.48) | AMY1ASELEIGF2RSTAT3FGF1 | |
| SCHEMBL14668930 | 0.81 | MEN1 (0.49) | AMY1AIGF2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9629865-B2 | Modified saponins for the treatment of fungal infections | THE BROAD INSTITUTE, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160228465-A1 | Modified Saponins For the Treatment of Fungal Infections | NIH - DEITR | 2016-08-11 | — | — | US | disclosed |
| US-8987217-B2 | Modified saponins for the treatment of fungal infections | THE GENERAL HOSPITAL CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130018007-A1 | Modified Saponins for the Treatment of Fungal Infections | THE BROAD INSTITUTE, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228465-A1 | Modified Saponins For the Treatment of Fungal Infections | ERG28, TREH, MANBA | AMY1A 227/4885SELE 2604/4885IGF2R 2541/4885 |
| US-20130018007-A1 | Modified Saponins for the Treatment of Fungal Infections | ERG28, TREH, MANBA | AMY1A 227/4885SELE 2604/4885IGF2R 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.